Nov 05, 2019
Curis Reports Third Quarter 2019 Financial Results
Oct 31, 2019
Oncology Care Model Poster Presented by AMCP Foundation and Genentech Intern
Oct 29, 2019
BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Oct 25, 2019
VISEN Pharmaceuticals announces China Phase 3 clinical study initiation for TransCon human growth hormone, the first unmodified long-acting growth hormone in China
Oct 22, 2019
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
Oct 18, 2019
Isofol Receives Positive Feedback From PMDA in Japan, Expanding Ongoing Global Pivotal Phase 3 AGENT Trial in First Line Metastatic Colorectal Cancer
Oct 11, 2019
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
Oct 09, 2019
Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target
Oct 08, 2019
Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
Sep 27, 2019
FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
Sep 27, 2019
Health Canada approves Tecentriq® in combination with chemotherapy (nab-paclitaxel) as first immunotherapy treatment for aggressive form of breast cancer(1)
Sep 26, 2019
Curis to Present at Cantor Fitzgerald Global Healthcare Conference
Sep 26, 2019
2019 Life Sciences Ideal Employers Identified in Latest BioSpace Report
Sep 25, 2019
BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
Sep 25, 2019
West Cancer Center and Research Institute partners with Roche Tissue Diagnostics - Enhancing Patient Care in the Histology Laboratory with Automation
Sep 23, 2019
ESMO Annual Meeting 2019: Menarini Ricerche Presents the Preclinical Characterization of MEN1611, a Novel PI3K Inhibitor in Development for the Treatment of Breast Cancer
Sep 20, 2019
Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
Sep 19, 2019
Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO
Sep 17, 2019
REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor
Sep 16, 2019
Anixa Biosciences Congratulates Scientific Advisory Board Member Dr. H. Michael Shepard as a 2019 Lasker Award Honoree